News & Updates

Alcohols and alcohol-based disinfectants are not strong enough to eliminate the hepatitis E virus (HEV), except for one commercial ethanol-based product that has phosphoric acid, a study has shown. This finding may help develop measures to reduce transmission in clinical practice.

The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.

Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.

In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.

People who experienced symptomatic COVID-19 are more likely to suffer from feelings of nervousness, anxiousness, and tension than those who had oligosymptomatic disease, a recent study has found. Such an effect appears to be pronounced in women and younger survivors.

Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.